Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial

Toms SA, et al.: J Neurooncol. 2019 Jan;141（2）:467-473. doi: 10.1007/s11060-018-03057-z.